Zoetis (ZTS) Competitors

Zoetis (NYSE:ZTS) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Do analysts recommend ZTS or IDXX?

Zoetis currently has a consensus target price of $212.13, indicating a potential upside of 38.75%. IDEXX Laboratories has a consensus target price of $558.11, indicating a potential upside of 5.97%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zoetis is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
IDEXX Laboratories	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Which has more volatility & risk, ZTS or IDXX?

Zoetis has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Is ZTS or IDXX more profitable?

Zoetis has a net margin of 27.12% compared to IDEXX Laboratories' net margin of 22.76%. IDEXX Laboratories' return on equity of 57.35% beat Zoetis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.12%	55.48%	19.14%
IDEXX Laboratories	22.76%	57.35%	26.97%

Does the media prefer ZTS or IDXX?

In the previous week, Zoetis had 2 more articles in the media than IDEXX Laboratories. MarketBeat recorded 32 mentions for Zoetis and 30 mentions for IDEXX Laboratories. Zoetis' average media sentiment score of 1.53 beat IDEXX Laboratories' score of 1.10 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	30 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IDEXX Laboratories	19 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, ZTS or IDXX?

Zoetis has higher revenue and earnings than IDEXX Laboratories. Zoetis is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.26B	7.35	$2.49B	$5.57	27.45
IDEXX Laboratories	$3.90B	10.87	$887.87M	$10.82	48.67

Do insiders & institutionals have more ownership in ZTS or IDXX?

92.8% of Zoetis shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Zoetis beats IDEXX Laboratories on 9 of the 16 factors compared between the two stocks.